EIS 12656
Alternative Names: EIS-12656Latest Information Update: 22 Sep 2024
Price :
$50 *
At a glance
- Originator Eisbach Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action CHD1L protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 16 Sep 2024 Pharmacodynamics data from a preclinical study in Solid tumours released by Eisbach Bio
- 09 Sep 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT06525298)
- 09 Sep 2024 Phase-I/II clinical trials in Solid tumours (Recurrent, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06525298)